Histone deacetylase inhibitor MS-275 alone or combined with bortezomib or sorafenib exhibits strong antiproliferative action in human cholangiocarcinoma cells.
about
The significance of genetics for cholangiocarcinoma developmentTargeting the IL-6 dependent phenotype can identify novel therapies for cholangiocarcinomaA phase II trial of the proteasome inhibitor bortezomib in patients with advanced biliary tract cancers.Impact of Salinomycin on human cholangiocarcinoma: induction of apoptosis and impairment of tumor cell proliferation in vitroRational therapeutic combinations with histone deacetylase inhibitors for the treatment of cancerInduction of differential apoptotic pathways in multiple myeloma cells by class-selective histone deacetylase inhibitors.EF24 inhibits tumor growth and metastasis via suppressing NF-kappaB dependent pathways in human cholangiocarcinoma.Synergistic combinations of signaling pathway inhibitors: mechanisms for improved cancer therapy.Evolving therapies in the treatment of hepatocellular carcinomaSynergistic activity of histone deacetylase and proteasome inhibition against pancreatic and hepatocellular cancer cell lines.Synergistic activity of vorinostat combined with gefitinib but not with sorafenib in mutant KRAS human non-small cell lung cancers and hepatocarcinoma.Emerging treatments for multiple myeloma: beyond immunomodulatory drugs and bortezomib.Targeted therapy in biliary tract cancer: 2009 update.Entinostat for treatment of solid tumors and hematologic malignancies.Therapeutic targeting of cancer cell cycle using proteasome inhibitorsInvolvement of insulin-like growth factor-binding protein-3 in the effects of histone deacetylase inhibitor MS-275 in hepatoma cells.HDAC inhibitors, MS-275 and salermide, potentiates the anticancer effect of EF24 in human pancreatic cancer cells.A phase I study of the histone deacetylase (HDAC) inhibitor entinostat, in combination with sorafenib in patients with advanced solid tumors.Critical analysis of simultaneous blockage of histone deacetylase and multiple receptor tyrosine kinase in the treatment of prostate cancer.Effect of histone deacetylase inhibitor on proliferation of biliary tract cancer cell lines.CG200745, an HDAC inhibitor, induces anti-tumour effects in cholangiocarcinoma cell lines via miRNAs targeting the Hippo pathway.Targeted medical therapy of biliary tract cancer: recent advances and future perspectives.Treatment of gastrointestinal neuroendocrine tumors with inhibitors of growth factor receptors and their signaling pathways: recent advances and future perspectives.Growth factor receptors and related signalling pathways as targets for novel treatment strategies of hepatocellular cancer.Cholangiocarcinoma - evolving concepts and therapeutic strategies.Perturbation of proteasome function by bortezomib leading to ER stress-induced apoptotic cell death in cholangiocarcinoma.Class I histone deacetylase inhibition improves pancreatitis outcome by limiting leukocyte recruitment and acinar-to-ductal metaplasia.The prostate cancer blocking potential of the histone deacetylase inhibitor LBH589 is not enhanced by the multi receptor tyrosine kinase inhibitor TKI258.
P2860
Q26865749-208C5D5B-AED2-48E7-BEC6-22F93428C2BDQ28476545-4B5B2F9B-6E01-477D-981C-A22B65C92F92Q34307050-8F82853A-CE0A-484F-92A8-018DE18BA032Q34443640-5F80E659-38DA-4878-9F59-BBCAC063C6CCQ35079955-95783AC8-9747-46C7-BB61-0D161CE344EDQ35509621-81CAFF6B-DDC6-416E-A84A-2EDD8D562E44Q37215717-901567FF-78F5-481C-A488-169D2F081B24Q37227994-2DC6B4EA-0ACE-4650-A4AA-19609338622AQ37290714-0B964A34-EB52-438B-9FCC-F16CF7DACA4CQ37400663-DF9C0764-3B8A-4339-BDE2-60E76DDA6804Q37413127-929C4108-2B2F-42A4-8F50-DACB45F1A0F9Q37457302-063A7F1D-4546-46F6-9149-4F72D36382F4Q37650623-B94A0F25-A0F4-4CA2-9726-2405B1983E46Q37925846-747D46C4-343F-4C39-A5BE-39A6E8D6B3E4Q38069898-E3A37C1C-0912-45F1-867E-FB28A8EA1C7DQ38675999-248289AE-ACD7-4D27-B453-2791082558EEQ38762886-6DDB8FEC-CDB8-4455-B73C-6AF449DF6476Q38942616-DB14BA67-277F-43FD-A682-5A0A1C9F5DBCQ39642981-096A3A08-6572-4AD1-AA9A-C2EDA60F14F9Q39987553-E9738D44-AD2C-4A8F-8683-D55EC4DD8350Q41546447-FC6AF2DD-D8C1-4AA9-9106-5915D389990DQ42635172-7868DED4-9765-487B-8291-4554F5027019Q43097453-82BA3281-4BC9-49EC-AF3F-640C06ACD59CQ43141124-5C862B6E-4D46-4CE9-9D98-A3D9C5E90794Q46087686-27267FFD-3247-4DD5-8CF1-A9AE43ECBBBFQ47955863-357AA837-C2E3-4DF3-9FD7-5C3AE5189FA9Q48194888-155DEE4F-19F5-4180-94DB-9EA2C172FB8EQ53156735-B2580D65-3B93-4B66-AA51-5420C377500D
P2860
Histone deacetylase inhibitor MS-275 alone or combined with bortezomib or sorafenib exhibits strong antiproliferative action in human cholangiocarcinoma cells.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Histone deacetylase inhibitor ...... uman cholangiocarcinoma cells.
@en
type
label
Histone deacetylase inhibitor ...... uman cholangiocarcinoma cells.
@en
prefLabel
Histone deacetylase inhibitor ...... uman cholangiocarcinoma cells.
@en
P2093
P2860
P356
P1476
Histone deacetylase inhibitor ...... uman cholangiocarcinoma cells.
@en
P2093
Alexander Huether
Detlef Schuppan
Hans Scherübl
Michael Höpfner
Viola Baradari
P2860
P304
P356
10.3748/WJG.V13.I33.4458
P407
P577
2007-09-01T00:00:00Z